Logo Image
|Videos|June 25, 2019

Inappropriate Empiric Therapy as a Driver of Poor Outcomes

Glenn Tillotson, PhD, explains how inappropriate empiric therapy can drive poor outcomes.

Segment Description: Glenn Tillotson, PhD, consultant with GST Micro and Contagion® Editorial Advisory Board member, explains how inappropriate empiric therapy can drive poor outcomes.

Interview transcript (modified slightly for readability):

Dr. Tillotson: "Inappropriate antibiotic empiric therapy is really recognized as a driver of poor outcomes such as longer length of stay in an intensive care unit, a longer length of stay in the hospital alone, prolonged antibiotic therapy, having to swap and change, and, in some skin infections, it actually can lead to mortality. So conditions such as abscesses that are inappropriately treated those can turn into complex challenges."

Related to this article

View more
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Read more
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Read more